DMA Diamedica Therapeutics

DiaMedica Inc., (TSX VENTURE:DMA) today announces the initiation of the
Company's autoimmune program with the success of DM-99 for the treatment of
rheumatoid arthritis and other autoimmune diseases.


DM-99 was found to reduce joint swelling by up to 90% (p less than 0.001) in a
collagen induced animal model of rheumatoid arthritis (RA) during the peak of
the disease. A single dose of the protein DM-99 administered at the first signs
of RA symptoms delayed the onset and severity of the disease. Furthermore,
treatment given every forth day appears to have halted the autoimmune attack
altogether. 


"We believe that DM-99 is able to activate or increase the number of regulatory
T cells (Tregs), which plays a vital role in suppressing the autoimmune attack
in a wide range of autoimmune diseases," commented Dr. Mark Williams,
DiaMedica's Vice President Research. 


In a delayed hypersensitivity model, skin inflammation was reduced by 67% (p
less than 0.05) and could be prevented for up to 14 days following a single
administration of DM-99. DM-99 also delayed skin graft rejection by several days
(p less than 0.05).


"Based on the ability of DM-99 to modulate the autoimmune attack in several
autoimmune diseases, we will be starting a study shortly to determine if our
more active form of DM-99, DM-199, can halt or slow the autoimmune attack in
type I diabetes. DM-199, may be the only compound that both proliferates beta
cells and protects them against the autoimmune attack in type I diabetes,"
stated Rick Pauls, President and CEO of DiaMedica.


About DiaMedica

DiaMedica is a biopharmaceutical company focused on developing novel treatments
for diabetes and neurological disorders. The Company's type 2 diabetes program
is based on a critical liver nerve signaling mechanism involved in enhancing
insulin sensitivity after meal consumption. Two of DiaMedica's products, DM-71
and DM-99, have previously demonstrated human efficacy in lowering blood sugar
levels in people diagnosed with type 2 diabetes based on this novel nerve
signaling mechanism.


DiaMedica has expanded its DM-199 recombinant protein program into neurological
and autoimmune disorders. The Company has demonstrated that DM-99, the naturally
occurring form of DM-199, confers neural protection (protects brain cells) and
triggers neural stem cell proliferation (creates brain cells) for the treatment
of numerous neurological disorders including Alzheimer's disease. DiaMedica is
listed on the TSX Venture Exchange under the trading symbol "DMA".


Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, the "forward-looking statements"). These
forward-looking statements relate to, among other things, DiaMedica's
objectives, goals, targets, strategies, intentions, plans, beliefs, estimates
and outlook, and can, in some cases, be identified by the use of words such as
"believe," "anticipate," "expect," "intend," "plan," "will," "may" and other
similar expressions. In addition, any statements that refer to expectations,
projections or other characterizations of future events or circumstances are
forward-looking statements. Specifically, this press release contains
forward-looking statements regarding matters such as, but not limited to, the
anticipated use of proceeds from the Offering, management's assessment of
DiaMedica's future plans, information with respect to the advancement of
DiaMedica's research and development programs, and DiaMedica's other estimates
and expectations. These statements reflect management's current beliefs and are
based on information currently available to management. Certain material factors
or assumptions are applied in making forward-looking statements, and actual
results may differ materially from those expressed or implied in such
statements. Important factors that could cause actual results to differ
materially from these expectations include, among other things: uncertainties
and risks related to our research and development programs, the availability of
additional financing, risks and uncertainties relating to the anticipated use of
proceeds, changes in debt and equity markets, uncertainties related to clinical
trials and product development, rapid technological change, uncertainties
related to forecasts, competition, potential product liability, additional
financing requirements and access to capital, unproven markets, the cost and
supply of raw materials, management of growth, effects of insurers' willingness
to pay for products, risks related to regulatory matters and risks related to
intellectual property matters. 

Additional information about these factors and about the material factors or
assumptions underlying such forward-looking statements may be found in the body
of this news release, as well as under the heading "Risk Factors" contained in
DiaMedica's 2009 annual information form. DiaMedica cautions that the foregoing
list of important factors that may affect future results is not exhaustive. When
relying on DiaMedica's forward-looking statements to make decisions with respect
to DiaMedica, investors and others should carefully consider the foregoing
factors and other uncertainties and potential events. Such forward-looking
statements are based on a number of estimates and assumptions, which may prove
to be incorrect, including, but not limited to, assumptions regarding the
availability of additional financing for research and development companies, and
general business and economic conditions. These risks and uncertainties should
be considered carefully and investors and others should not place undue reliance
on the forward-looking statements. Although the forward-looking statements
contained in this press release are based upon what management believes to be
reasonable assumptions, DiaMedica cannot provide assurance that actual results
will be consistent with these forward-looking statements. DiaMedica undertakes
no obligation to update or revise any forward-looking statement. Additional risk
factors, factors which could cause actual results to differ materially from
expectations, and assumptions relating specifically to our acquisition of
Sanomune may be found in our press releases dated February 18, 2010 and April
20, 2010.

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024